Frazier Life Sciences Management L.P. Makes New $31.93 Million Investment in Aura Biosciences, Inc. $AURA

by · The Cerbat Gem

Frazier Life Sciences Management L.P. acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,100,000 shares of the company’s stock, valued at approximately $31,926,000. Aura Biosciences accounts for 1.3% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 18th biggest holding. Frazier Life Sciences Management L.P. owned about 10.15% of Aura Biosciences as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nantahala Capital Management LLC increased its holdings in Aura Biosciences by 67.1% in the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock worth $13,257,000 after purchasing an additional 850,000 shares in the last quarter. Long Focus Capital Management LLC grew its position in shares of Aura Biosciences by 30.8% during the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock worth $19,453,000 after buying an additional 781,808 shares during the period. Acorn Capital Advisors LLC bought a new stake in shares of Aura Biosciences in the 1st quarter valued at $3,460,000. Levin Capital Strategies L.P. lifted its position in shares of Aura Biosciences by 9.9% during the 2nd quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company’s stock valued at $9,362,000 after acquiring an additional 134,792 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Aura Biosciences by 5.9% during the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock valued at $14,653,000 after acquiring an additional 130,221 shares during the period. Institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

AURA has been the subject of a number of research reports. Zacks Research upgraded shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday. Finally, Evercore ISI began coverage on Aura Biosciences in a research report on Tuesday, November 25th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Get Our Latest Analysis on AURA

Aura Biosciences Trading Up 0.5%

Aura Biosciences stock opened at $6.54 on Friday. The firm has a market capitalization of $415.29 million, a price-to-earnings ratio of -3.37 and a beta of 0.44. The firm’s fifty day moving average price is $5.96 and its two-hundred day moving average price is $6.28. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $9.04.

Aura Biosciences (NASDAQ:AURA – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. On average, research analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Insiders Place Their Bets

In related news, CTO Mark Plavsic sold 12,169 shares of the stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $6.35, for a total value of $77,273.15. Following the completion of the sale, the chief technology officer directly owned 197,287 shares of the company’s stock, valued at approximately $1,252,772.45. This represents a 5.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Los Pinos Elisabet De sold 9,049 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $6.35, for a total value of $57,461.15. Following the transaction, the insider owned 474,391 shares in the company, valued at approximately $3,012,382.85. This trade represents a 1.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 39,223 shares of company stock valued at $233,155. Corporate insiders own 6.30% of the company’s stock.

Aura Biosciences Company Profile

(Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Recommended Stories